phrykt

Collegium Pharmaceutical, Inc (COLL): who owns it and who trades it

As of Nov 16, 2026, COLL insiders reported 11 open-market sales worth $4.4M and no purchases in the last 12 months, with 82% of the sale value made under pre-set 10b5-1 plans. The largest seller was Scott Dreyer (Vice president), with $2.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Collegium Pharmaceutical

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns COLL

277 funds and institutions reported COLL shares worth $1.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.8%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.16.8%
Jupiter Topco LLC6.6%
Invesco Ltd.5.8%
Fuller & Thaler Asset Management, Inc.5.0%
Principal Financial Group Inc5.0%
California State Teachers Retirement System4.8%
State Street Corp4.7%
Massachusetts Financial Services Co4.3%
Vanguard Capital Management LLC4.3%
Renaissance Technologies LLC4.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.44M16.78%$197M+6%
Jupiter Topco LLC2.15M6.62%$77.7M–
Invesco Ltd.1.88M5.80%$68.1M+18%
Fuller & Thaler Asset Management, Inc.1.63M5.03%$59.1M+9%
Principal Financial Group Inc1.63M5.03%$59.1M+26%
California State Teachers Retirement System1.55M4.78%$42.8M+5166%
State Street Corp1.53M4.71%$55.3M+7%
Massachusetts Financial Services Co1.41M4.33%$50.9M+3%
Vanguard Capital Management LLC1.38M4.26%$50M+4%
Renaissance Technologies LLC1.37M4.21%$49.5M-7%
Eventide Asset Management, LLC1.36M4.20%$49.3M-4%
Rubric Capital Management LP1.28M3.95%$46.3MNo change
Geode Capital Management, LLC890,8862.75%$32.3M+9%
Dimensional Fund Advisors LP837,8772.58%$30.3M+1%
Victory Capital Management Inc760,2522.34%$27.5M+22%
Goldentree Asset Management LP744,8892.30%$26.9M–
Vanguard Portfolio Management LLC740,0812.28%$26.8M+9%
Millennium Management LLC736,9252.27%$26.7M+104%
Arrowstreet Capital, Limited Partnership621,9201.92%$22.5M-12%
Assenagon Asset Management S.A.617,8341.90%$22.4M+98%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, COLL insiders reported $0 of open-market purchases and $4.4M of sales. 82% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4.4M
11 trades, 6 people
Sales under a 10b5-1 plan
82%
Share of sale value
Latest trade
May 18, 2026
Filed May 20, 2026

Purchases and sales by month

$2.7M$2.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 18, 2026John Gordon FreundDirectorSale20$34.05$681Form 4
May 15, 2026John Gordon FreundDirectorSale4,127$34.54$143KForm 4
May 13, 2026Nancy LurkerDirectorSale4,500$35.97$162KForm 4
May 11, 2026Garen G BohlinDirectorSale8,700$37.18$323KForm 4
Mar 18, 2026David DieterVice presidentSale plan13,976$34.92$488KForm 4
Mar 9, 2026David DieterVice presidentSale plan6,224$36.65$228KForm 4
Mar 3, 2026Scott DreyerVice presidentSale plan3,559$40.99$146KForm 4
Mar 3, 2026Scott DreyerVice presidentSale plan46,417$40.36$1.9MForm 4
Dec 8, 2025Scott DreyerVice presidentSale plan11,125$47.89$533KForm 4
Dec 8, 2025Scott DreyerVice presidentSale plan6,475$48.66$315KForm 4
Dec 5, 2025Rita J. Balice-GordonDirectorSale3,650$47.03$172KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Scott DreyerEVP & Chief Commercial Officer–$2.9MMar 3, 2026
David DieterEVP & General Counsel–$716KMar 18, 2026
Garen G BohlinDirector–$323KMay 11, 2026
Rita J. Balice-GordonDirector–$172KDec 5, 2025
Nancy LurkerDirector–$162KMay 13, 2026
John Gordon FreundDirector–$143KMay 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

COLL short interest

High short interest. 16.0% of COLL shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.19M COLL shares were sold short, 16.0% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 552,891 shares, buying them all back would take about 9.4 trading days (days to cover).

Shares short, % of all shares

16.0%May 15Oct 3020.7%

Days to cover

9.4May 15Oct 3019.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.19M15.96%-3%552,8919.4
Oct 15, 20265.38M16.51%-3%749,8707.2
Sep 30, 20265.52M16.95%-3%910,9226.1
Sep 15, 20265.68M17.43%-6%941,4306.0
Aug 31, 20266.06M18.63%-7%750,6358.1
Aug 14, 20266.52M20.04%+28%979,4716.7
Jul 31, 20265.08M15.61%-3%292,83617.4
Jul 15, 20265.23M16.14%-4%467,57511.2
Jun 30, 20265.47M16.85%+3%504,46210.8
Jun 15, 20265.33M16.43%-6%407,62613.1
May 29, 20265.66M17.46%-5%318,27317.8
May 15, 20265.97M18.39%+0%533,61911.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Collegium Pharmaceutical company events

Collegium Pharmaceutical filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026AgreementEnded an important agreement. Filing
  3. Aug 13, 2026AnnouncementCollegium Pharmaceutical, Inc. announced the execution of an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. May 15, 2026VoteReported shareholder vote results. Filing
  6. May 12, 2026LeadershipThe Company’s board of directors adopted the Company’s 2026 Inducement Plan, pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with respect to an… Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 7, 2026LeadershipThe board of directors of Collegium Pharmaceutical, Inc. approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders. Filing
  9. Mar 19, 2026AgreementCollegium Pharmaceutical, Inc., entered into an Equity Purchase Agreement with Corium Therapeutics Holdings, LLC, a Delaware limited liability company, and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and, together with Commave Seller, the “ Seller Parties ” and each, a “… Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Jan 8, 2026AnnouncementShared information with investors. Filing
  12. Dec 30, 2025AgreementEntry into a Material Agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Collegium Pharmaceutical financials

Famous investors that hold COLL

4 of the 50 well-known investors we track reported holding COLL in their latest 13F filing. The largest position is Israel Englander's, worth $52.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.40M$52.4M0.0%+226%
Jim Simons · Renaissance TechnologiesQ3 20261.41M$30.7M0.0%+3%
Ken Griffin · Citadel AdvisorsQ3 2026602,530$13.1M0.0%+778%
Steve Cohen · Point72 Asset ManagementQ3 2026209,797$4.6M0.0%+84%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named COLL in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.2%
Nov 16, 2026FULLER & THALER ASSET MANAGEMENT, INC.13G/A1.8%
Nov 16, 2026FULLER & THALER ASSET MANAGEMENT, INC.13G/A1.8%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.2%
Nov 10, 2026STATE STREET CORPORATION13G5.4%
Nov 10, 2026STATE STREET CORPORATION13G5.4%
Nov 10, 2026Invesco Ltd.13G/A3.9%
Nov 10, 2026Invesco Ltd.13G/A3.9%
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 29, 2026PRINCIPAL GLOBAL INVESTORS13G/A4.7%
Oct 29, 2026PRINCIPAL GLOBAL INVESTORS13G/A4.7%
Oct 8, 2026Integrated Core Strategies (US) LLC13G/A5.8%
Oct 8, 2026Integrated Core Strategies (US) LLC13G/A5.8%

Questions about Collegium Pharmaceutical, Inc (COLL) stock

Who owns the most COLL stock?

The largest reported owner of Collegium Pharmaceutical, Inc (COLL) is BlackRock, Inc., with 16.8% of the company. In total, 277 funds and institutions reported holding COLL at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are COLL insiders buying or selling?

In the last 12 months, COLL insiders reported no open-market purchases and 11 sales worth $4.4M. The latest trade was on May 18, 2026. See every trade.

What is the short interest in COLL?

As of Oct 30, 2026, 5.19M COLL shares were sold short, 16.0% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 552,891 shares, buying them all back would take about 9.4 trading days (days to cover). See the history.

Which famous investors hold COLL?

4 of the 50 well-known investors we track reported COLL in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $52.4M. See all holders.

Executive pay

Collegium Pharmaceutical's chief executive was paid a total of $1.7M for the year ended Dec 31, 2025. In the last 12 months, Collegium Pharmaceutical's executives and directors bought no stock on the open market and sold $4.4M.

Chief executive, total pay$1.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.